HIGH THROUGH-PUT DISCOVERY OF MALARIA DRUG TARGETS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$284,047.00
Award Year:
2002
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI051776-01
Agency Tracking Number:
AI051776
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
COMPLEGEN, INC.
COMPLEGEN, INC., 1124 COLUMBIA ST, STE 662, SEATTLE, WA, 98104
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOHN SWINDLE
(206) 447-8076
JSWINDLE@COMPLEGEN.COM
Business Contact:
JOEL HEDGPETH
(206) 447-8076
Research Institution:
n/a
Abstract
DESCRIPTION (Provided by applicant): Emerging and re-emerging infectious diseases are some of the most important contributors to pain, suffering and poverty in the developing world. For parasitic diseases in general, vaccines are nonexistent and none are likely to have a significant impact in the foreseeable future. In the case of malaria, without a vaccine on the horizon and an increasing prevalence of resistance to commonly used therapeutic drugs, the need for additional anti-malarial drug development is obvious. However, several factors, including increased cost of development, have lead to the retreat of most pharmaceutical companies from the development of new anti-malarial therapeutics. The research and development described in this proposal utilizes a new cost effective approach to anti-malarial drug target discovery. We will use a comparative approach to identify potential therapeutic targets common to Plasmodium falciparum, Toxoplasma gondii and Eimeria tenella. This work will form the basis for a future phase II application, which will use the reagents developed here to identify broad spectrum apicomplexan specific inhibitor compounds.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government